Xspray Pharma AB

Equities

XSPRAY

SE0009973563

Biotechnology & Medical Research

Delayed Nasdaq Stockholm Other stock markets 08:01:14 2024-05-17 am EDT			5-day change	1st Jan Change
53.8 ^SEK	+3.86%		+26.00%	+34.50%

Apr. 22	Xspray Pharma Announces Fourth Product Candidate, Targeting USD 2.3 Billion Market	CI
Feb. 14	Xspray Pharma AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	CI

Xspray Pharma Q3 2023 - Approaching Commercialization

November 09, 2023 at 02:45 am EST

Redeye makes minor changes to its fair value range following Xspray Pharma’s Q3 report, which contained no major surprises. We continue to observe a disconnect between operational newsflow and the share price as Xspray proceeds toward FDA approval and the anticipated Q3 2024 launch of Dasynoc.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Latest news about Xspray Pharma AB

Xspray Pharma Announces Fourth Product Candidate, Targeting USD 2.3 Billion Market	Apr. 22	CI
Xspray Pharma AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 14	CI
US FDA Accepts Xspray Pharma's Refiled Application for Potential Leukemia Treatment	Feb. 12	MT
FDA Accepts Xpray Pharma's NDA-Resubmission for Dasynoc® - PDUFA	Feb. 12	CI
Xspray Pharma AB Appoints Kerstin Hasselgren as Head of IR	Feb. 07	CI
Xspray Pharma AB Announces CFO Changes	Feb. 07	CI
Xspray Pharma Ab's Xs003 Achieves Superior Bioavailability Milestone, Matching TASIGNA At Reduced Dosage	Nov. 21	CI
Xspray Pharma AB Through HyNap? technology Announces Results from Drug Interaction Studies	Nov. 08	CI
Xspray Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Xspray Pharma AB Announces Nomination Committee for the Annual General Meeting 2024	23-10-24	CI
Certain Shares of Xspray Pharma AB are subject to a Lock-Up Agreement Ending on 25-SEP-2023.	23-09-24	CI
Xspray Pharma Names Chief Commercial Officer	23-09-15	MT
Xspray Pharma Appoints Edward P. Jordan as Chief Commercial Officer	23-09-15	CI
Xspray Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-02	CI
US FDA Requests More Data from Xspray Pharma for Dasynoc Drug Candidate; Shares Fall 7%	23-07-11	MT
Xspray Pharma AB Receives Request for Additional Information Concerning Dasynoc from FDA	23-07-11	CI
Xspray Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04	CI
Xspray Pharma AB Auditor Raises 'Going Concern' Doubt	23-03-28	CI
Xspray Pharma AB Partners with EVERSANA® for the U.S. Launch and Commercialization of its Lead Product, Dasynoc for the Treatment of Chronic Myeloid Leukemia and Acute Lymphatic Leukemia	23-02-23	CI
Xspray Pharma AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-15	CI
Xspray Pharma AB Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-15	CI
Xspray Pharma AB(OM:XSPRAY) added to OMX Nordic Small Cap Index	23-01-03	CI
Xspray Pharma AB's Drug Candidate Xs004 Granted Orphan Drug Designation in the US for the Treatment of Acute Lymphoblastic Leukemia	22-11-30	CI
Xspray Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-09	CI
Xspray Pharma AB Announces Nomination Committee for the Annual General Meeting 2023	22-10-25	CI

Chart Xspray Pharma AB

Duration

Period

More charts

Company Profile

XSpray Pharma AB (publ), formerly Xspray Microparticles AB, is a Sweden-based biotechnology company. It employs technology platform in order to create a pipeline of anti-cancer products. The Company primarily develops protein kinase inhibitors (PKI) for targeted cancer treatments. The product candidates include Sprycel, also known as HyNap-Dasa, (version of dasatinib medicine), Tasigna, also under name HyNap-Nilo, (version of nilotinib medicine) and Nexavar, also is under name HyNap-Sora, (version of sorafenib medicine), among others. Sprycel and Tasigna are indicated for treatment of adult patients diagnosed with Philadelphia chromosome-positive (pH+) chronic myeloid leukemia (CML). Sprycel is also indicated for the treatment of adult patients with pH+ acute lymphocytic leukemia (ALL) and lymphoid blastic CML with resistance or intolerance to prior treatment. Nexavar is indicated for the treatment of patients with liver cell cancer, renal cell cancer and differentiated thyroid cancer.

Sector

Biotechnology & Medical Research

Calendar

2024-05-21 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

51.8 SEK

Average target price

107 SEK

Spread / Average Target

+106.56%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
XSPRAY PHARMA AB	+34.50%	151M
VERTEX PHARMACEUTICALS INCORPORATED	+8.29%	114B
REGENERON PHARMACEUTICALS, INC.	+10.21%	104B
BIONTECH SE	-11.90%	22.41B
ARGENX SE	+0.23%	22.28B
GENMAB A/S	-5.57%	19.07B
WUXI APPTEC CO., LTD.	-37.36%	18B
BEIGENE, LTD.	-5.17%	17.89B
NEUROCRINE BIOSCIENCES, INC.	+7.70%	14.28B
SAREPTA THERAPEUTICS, INC.	+37.65%	12.55B

Bio Therapeutic Drugs